OncoSec Medical

Heat Biologics, OncoSec Medical collaborate on immunotherapy platforms

Thursday, February 19, 2015 02:38 PM

Heat Biologics, a clinical stage biopharmaceutical company developing cancer immunotherapies based in Durham, N.C., and OncoSec Medical, a San Diego, Calif.-based company developing DNA-based intratumoral cancer immunotherapies, have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company.

More... »


OncoSec Medical, University of Washington ink research agreement

Friday, November 21, 2014 11:20 AM

OncoSec Medical, a San Diego-based company developing DNA-based intratumoral cancer immunotherapies, has entered a sponsored research agreement (SRA) with the University of Washington to evaluate the immunologic mechanisms of intratumoral DNA IL-12 electroporation.

More... »


OncoSec establishes UCSF clinical site for phase II Merkel cell carcinoma trial

Wednesday, July 11, 2012 10:22 AM

OncoSec Medical, a biopharmaceutical company developing the advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumors, has established the University of California San Francisco (UCSF) as the second enrolling site for its phase II Merkel cell carcinoma study (OMS-I110).

More... »

OncoSec doses first patients in phase II Merkel cell carcinoma study

Monday, February 13, 2012 03:22 PM

OncoSec Medical has treated several patients in an open-label, phase II clinical trial evaluating OncoSec's OMS (OncoSec Medical System) ElectroImmunotherapy for the treatment of Merkel cell carcinoma (MCC).

More... »

OncoSec names Brain McCluskey engineering leader

Wednesday, July 6, 2011 10:50 AM

OncoSec Medical has named Brian McCluskey executive director of engineering, to lead the development of the company's proprietary electroporation delivery technology, the OncoSec Medical System (OMS).

More... »


CWWeekly

February 23

Venture capital investors funding novel drug R&D three times more than companies repurposing, improving existing drugs

In appreciation: Karen Woodin will be remembered for her teaching, writing and lasting friendships

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

February

Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs